Literature DB >> 20483757

F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells.

Jayati Mookerjee-Basu1, Pierre Vantourout, Laurent O Martinez, Bertrand Perret, Xavier Collet, Christian Périgaud, Suzanne Peyrottes, Eric Champagne.   

Abstract

Human Vgamma9Vdelta2 T lymphocytes are activated by phosphoantigens provided exogenously or produced by tumors and infected cells. Activation requires a contact between Vgamma9Vdelta2 cells and neighboring cells. We previously reported a role for cell surface F1-adenosine triphosphatase (ATPase) in T cell activation by tumors and specific interactions between Vgamma9Vdelta2 TCRs and purified F1-ATPase. 721.221 cells do not express surface F1-ATPase and do not support phosphoantigen responses unless they are rendered apoptotic by high doses of zoledronate, a treatment that promotes F1-expression as well as endogenous phosphoantigen production. By monitoring calcium flux in single cells, we show in this study that contact of T cells with F1-ATPase on polystyrene beads can partially replace the cell-cell contact stimulus during phosphoantigen responses. Triphosphoric acid 1-adenosin-5'-yl ester 3-(3-methylbut-3-enyl) ester, an adenylated derivative of isopentenyl pyrophosphate, can stably bind to F1-ATPase-coated beads and promotes TCR aggregation, lymphokine secretion, and activation of the cytolytic process provided that nucleotide pyrophosphatase activity is present. It also acts as an allosteric activator of F1-ATPase. In the absence of Vgamma9Vdelta2 cells, triphosphoric acid 1-adenosin-5'-yl ester 3-(3-methylbut-3-enyl) ester immobilized on F1-ATPase is protected from nucleotide pyrophosphatase activity, as is the antigenic activity of stimulatory target cells. Our experiments support the notion that Vgamma9Vdelta2 T cells are dedicated to the recognition of phosphoantigens on cell membranes in the form of nucleotide derivatives that can bind to F1-ATPase acting as a presentation molecule.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20483757     DOI: 10.4049/jimmunol.0904024

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

Review 1.  Ecto-F₁-ATPase: a moonlighting protein complex and an unexpected apoA-I receptor.

Authors:  Pierre Vantourout; Claudia Radojkovic; Laeticia Lichtenstein; Véronique Pons; Eric Champagne; Laurent O Martinez
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

Review 2.  Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

Authors:  Hamid Reza Mirzaei; Hamed Mirzaei; Sang Yun Lee; Jamshid Hadjati; Brian G Till
Journal:  Cancer Lett       Date:  2016-07-05       Impact factor: 8.679

Review 3.  Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.

Authors:  Barbara Castella; Candida Vitale; Marta Coscia; Massimo Massaia
Journal:  Cell Mol Life Sci       Date:  2011-05-17       Impact factor: 9.261

Review 4.  Mitochondria: master regulators of danger signalling.

Authors:  Lorenzo Galluzzi; Oliver Kepp; Guido Kroemer
Journal:  Nat Rev Mol Cell Biol       Date:  2012-12       Impact factor: 94.444

Review 5.  Defining the nature of human γδ T cells: a biographical sketch of the highly empathetic.

Authors:  Shirin Kalyan; Dieter Kabelitz
Journal:  Cell Mol Immunol       Date:  2012-10-22       Impact factor: 11.530

6.  Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens.

Authors:  Morgane Moulin; Javier Alguacil; Siyi Gu; Asmaa Mehtougui; Erin J Adams; Suzanne Peyrottes; Eric Champagne
Journal:  Cell Mol Life Sci       Date:  2017-07-01       Impact factor: 9.261

7.  Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human γδ T cells to induce innate anti-tumor/virus immunity.

Authors:  Yumei Dai; Hui Chen; Chen Mo; Lianxian Cui; Wei He
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

Review 8.  Role of gamma-delta T-cells in cancer: another opening door to immunotherapy.

Authors:  Diego Marquez-Medina; Joel Salla-Fortuny; Antonieta Salud-Salvia
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

Review 9.  γδ T cell receptor ligands and modes of antigen recognition.

Authors:  Eric Champagne
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2011-02-06       Impact factor: 4.291

Review 10.  Six-of-the-best: unique contributions of γδ T cells to immunology.

Authors:  Pierre Vantourout; Adrian Hayday
Journal:  Nat Rev Immunol       Date:  2013-02       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.